Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses


Supernus Pharmaceuticals reported $122.39M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Pacira USD 91.87M 70K Dec/2025
Perrigo USD 255.9M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025